Despite positive initial steps, further progress is needed from Chinese officials to create a more predictable and transparent regulatory environment ... the National Medical Products Administration ...

Explore China's 2024 TMT sector developments, from AI governance to online sales and industrial transformation. Discover key ...

However, the yearly inspection results of clinical trial projects published by the National Medical Products Administration (NMPA) and its provincial branches ... the management of institutional ...

Three days have passed since Bianca Censori decided to break the internet by showing up on the red carpet at the Grammy Awards in a transparent dress, baring her body completely uncensored and ...

Mangaluru: An expert committee constituted to examine the Kulai fishing harbour works has suggested the New Mangaluru Port Authority (NMPA) continue with the works and ensure that the quality and ...

This is the NMPA's latest retaliation against Spotify since the streaming service reclassified its premium subscriptions as 'bundles' in March, lowering royalties for publishers. By Kristin ...

The National Music Publishers’ Association (NMPA) has launched an ongoing takedown initiative against Spotify over the unlicensed use of music in podcasts on its platform. Notices will be sent ...

Building on this legacy of innovation, LG did the unthinkable yet again with the announcement of the first-ever transparent OLED TV in the world in 2024. LG's see-through 77" TV with 4K UHD ...

The NMPA constituted the committee with the approval of its board to examine the concerns about the project by the local fishermen. As suggested by the committee, Real Time Kinematic (RTK ...

Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR ...

A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review.

Acceptance of the drug application by the NMPA marks an essential step in introducing NVK002 as a potential therapeutic option for managing myopia in children across China. “NMPA acceptance of ...